Pancreatic cancer is one of the toughest cancers to beat. It grows fast, hides well, and resists most treatments. But now, a team of scientists in Spain has made a big step forward. They've found a way to wipe out this aggressive cancer in mice. The secret? A triple-drug combo that attacks the cance
Chordoma is a tough cancer to treat. It's rare, and doctors don't have many options. But there's a new drug called palbociclib that might help. Researchers tested palbociclib on people with advanced chordoma. They wanted to see if it could stop the cancer from growing. The results are promising. P
Afatinib and capecitabine are two drugs that are being tested together in a clinical trial. This trial is for people who have cancers that are hard to treat. These cancers include pancreatic ductal adenocarcinoma, biliary tract cancers, and other solid tumors. The epidermal growth factor re
Atrial fibrillation, or AFib, is a heart condition that affects millions worldwide. It's a problem where the heart beats irregularly, which can lead to serious health issues. Two main treatments exist: drug therapy and ablation. Drug therapy involves taking medication to control the heart's rhythm.
Metastatic colorectal cancer (mCRC) is a challenge for doctors. It is important to try to keep patients' quality of life while also extending their lives. Doctors also want to avoid harmful side effects. We have several treatments, but choosing the right one can be tricky, especially since differen
The need to find new treatment options for patients with advanced colon cancer has always been a challenge for doctors. The medical community has been using a combination of FOLFOXIRI and bevacizumab as a first line treatment. This is a potent cocktail of chemotherapy drugs that fight cancer cells i
Hidradenitis suppurativa (HS) and psoriasis are both long-term inflammatory conditions that share similar immune system pathways. Both diseases involve cytokines like tumor necrosis factor-alpha, interleukin (IL)-17, and IL-23. Currently, treatment choices for HS are limited, with only adalimumab an
